Valproic acid: An anticonvulsant drug with potent antinociceptive and anti-inflammatory properties

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 7, 2013, Pages 575-587

  Ximenes, José Christian Machado ^c   De Oliveira Gonçalves, Danilo ^a   Siqueira, Rafaelly Maria Pinheiro ^a   Neves, Kelly Rose Tavares ^a   Santos Cerqueira, Gilberto ^a   Correia, Alyne Oliveira ^b   Félix, Francisco Hélder Cavalcante ^d   Leal, Luzia Kalyne Almeida Moreira ^a   De Castro Brito, Gerly Anne ^a   Da Graça Naffah Mazzacorati, Maria ^c   De Barros Viana, Glauce Socorro ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Faculty of Medicine of Juazeiro do Norte (FMJ)   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Albert Sabin Hospital   (Brazil)

Author keywords

Cytokines; Inflammation; Nociception; Valproic acid sodium valproate

Indexed keywords

BUTYRIC ACID; CARRAGEENAN; EOSIN; FORMALDEHYDE; HEMATOXYLIN; INDOMETACIN; MORPHINE; MYELOPEROXIDASE; NALOXONE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME RELEASE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; MOUSE; NOCICEPTION; NONHUMAN; PAW EDEMA; PERITONEUM EXUDATE; PERITONITIS; RAT; REACTION TIME; THERMAL STIMULATION;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; BUTYRIC ACID; CARRAGEENAN; DRUG SYNERGISM; EDEMA; FOOT; FORMALDEHYDE; HOT TEMPERATURE; HYDROXAMIC ACIDS; LEUKOCYTE COUNT; MALE; MICE; PAIN; PENTOXIFYLLINE; PERITONITIS; PEROXIDASE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; VALPROIC ACID;

EID: 84879117025     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0853-4     Document Type: Article

References (68)

1. Adcock IM (2007) HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150:829-831
2. Bai G, Wei D, Zou S, Ren K, Dubner R (2010) Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain 6:51-62
3. Barnes PJ (2006) How corticosteroids control inflammation, Quintiles Prize Lecture 2005. Br J Pharmacol 148:245-254
4. Berrino L, Oliva P, Massino F, Aurilio C, Maione S, Grella A, Rossi F (2003) Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate receptor. Eur J Pain 7:131-137
5. Biermann J, Griesbaber P, Goebel U, Martin G, Thanos S, Giovanni SD, Lagrèze WA (2010) Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells. Invest Ophthalmology Vision Sci 51:526-534
6. Cardinale JP, Sriramula S, Pariault R, Guggilam A, Mariapan N, Elks CM, Francis J (2010) HDAC inhibition attenuates inflammatory, hypertrophic and hypertensive responses in spontaneously hypertensive rats. Hypertension 56:437-444
7. Chen Q, Ouyang DY, Geng M, Xu LH, Zhang YT, Wang FP, He XH (2011) Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol 8:210-218
8. Chen Y, Boettger MK, Reif A, Schmitt A, Üçeyler N, Sommer C (2010) Nitric oxide synthase modulates CFA-induced thermal hyperalgesia through cytokine regulation in mice. Molecular Pain 6:13-23
9. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY (2005) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin and Exp Allergy 35:89-96
10. Choi Y, Park S-K, Kim HM, Kang JS, Yoon YD, Han SB, Han JW, Yang JS, Han G (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endoxemia model. Exp and Mol Med 40:574-581
11. Chung YL, Lee MY, Wang AJ, Yao LF (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8:707-717
12. Cunha F, Poole S, Lorenzetti B, Ferreira S (1992) The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107:660-664
13. Dawson J, Sedgwick AD, Edwards JC, Lees P (1991) A comparative study of the cellular, exudative and histological responses to carrageenan, dextran and zymosan in the mouse. IntJ of Tissue Reactants 13:171-185
14. Dinarello CA (2006) Cytokines as potential therapeutic targets for inflammatory skin diseases. Ernst Schering Found Symp Proc 56:45-60
15. Di Paola R, Di Marco R, Mazzon E, Genovese T, Bendtzen K, Macrì B, Nicoletti F, Cuzzocrea S (2004) Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. Clin Immunol 113:64-73
16. Eisenberg E, Vos BP, Strassman AM (1993) The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain 54:301-307
17. Ferreira S, Lorenzetti B, Bristow A, Poole S (1988) Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334:698-700
18. Furumai R, Ito A, Ogawa K, Maeda S, Saito A, Nishino N, Horinouchi S, Yoshida M (2011) Histone deacetylase inhibitors block nuclear factor-kB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci 102:1081-1087
19. Gordon SM, Dionne RA, Brahim J, Jabir F, Dubner R (1997) Blockade of peripheral neuronal barrage reduces postoperative pain. Pain 70:209-215
20. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
21. Gottschalk A, Smith DS, Jobes DR, Kennedy SK, Lally SE, Noble VE, Grugan KF, Seifert HA, Cheung A, Malkowicz SB et al (1998) Preemptive epidural analgesia and recovery from radical prostatectomy: a randomized controlled trial. JAMA 279:1076-1082
22. Grabiec AM, Krausz S, Jager W, Burakowski T, Groot D, Sanders ME, Prakken BJ, Maslinski W, Eldering E, Tak PP, Reedquist KA (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 184:2718-2728
23. Grayson DR, Kundakovic M, Sharma RP (2010) Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77:126-135
24. Guay J, Bateman K, Gordon R, Mancini J, Riendeau D (2004) Carrageenan-induced paw edema in rat elicits a predominant prostaglandins E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 279:24866-24873
25. Halili MA, Andrews M, Sweet M, Fairlie DP (2009) Histone deacetylase inhibitors in inflammatory disease. Curr Topics in Med Chem 9:309-319
26. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S (2000) Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 857:246-251
27. Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M, Adcock IM, Moilanen E, Zhang X (2010) Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. J Inflamm 7:9-23
28. Kataoka T, Teraoka J, Sakoda A, Nishiyama Y, Yamoto K, Monden M, Ishimori Y, Nomura T, Taguchi T, Yamaoka K (2012) Protective effects of radon inhalation on carrageenan-induced inflammatory paw edema in mice. Inflammation 35:713-722
29. Khan MIA, Walsh D, Brito-Dellan N (2011) Opioid and adjuvant analgesics: compared and contrasted. Am J Hospital Palliative Care 28:378-383
30. Krämer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Göttlicher M (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411-3420
31. Lee IO, Kong MH, Kim NS, Choi YS, Lim SH, Lee MK (2000) Effect of different concentrations and volumes of formalin on pain response in rats. Acta Anaesthesiologica Sinica 38:59-64
32. Leng Y, Chuang DM (2006) Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26:7502-7512
33. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL et al (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11:1-15
34. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc National Acad Sci USA 99:2995-3000
35. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S (2011) Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Diseases 10:49
36. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397-413
37. Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D (2007) Cytokine profiles during carrageenan-induced inflammatory hyperalgesia in rat muscle and hind paw. J Pain 8:127-136
38. Loscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:669-694
39. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Ad in Cancer 91:137-168
40. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (1999) Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 159:508-511
41. Milutinovic S, D'Alessio AC, Detich N, Szyf M (2006) Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 28:560-571
42. Moradei O, Maroun CR, Paquin I, Vaisburg A (2005) Histone deacetylase inhibitors: latest developments, trends and prospects. Curr Med Chem Anti-Cancer Agents 5:529-560
43. Nalivaeva NN, Belyaev ND, Turner AJ (2009) Sodium valproate: an old drug with new roles. Trends in Pharmacol Sci 30:509-514
44. Ni YF, Wang J, Yan XL, Tian F, Zhao JB, Wang YJ, Jiang T (2010) Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respir Res 11:33-40
45. O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH (2000) Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 880:84-91
46. Ohuchi K, Sato H, Tsurufuji S (1976) The content of prostaglandin E and prostaglandin F2-α in the exudate of carrageenan granuloma of rats. Biochem and Biophys Acta 424:439-448
47. Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695-714
48. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
49. Piovesan EJ, Randunz V, Utiumi M, Lange MC, Kowacs PA, Mulinari RA, Oshinski M, Vital M, Sereniki A, Fernandes AF, Silva LL, Werneck LC (2008) Influence of NMDA and non-NMDA antagonists on acute and inflammatory pain in the trigeminal territory. Arquivos de Neuropsiquiatria 66:837-843
50. Raza M, Dhariwal MA, Ageel AM, Quresh S (1996) Evaluation of the anti-inflammatory activity of sodium valproate in rats and mice. Gen Pharmacol 27:1395-1400
51. Roberge RJ, Francis EH (2002) Use of naloxone in valproic acid overdose: case report and review. J Emergency Med 22:67-70
52. Rocha AC, Fernandes ES, Quintão NL, Campos MM, Calixto JB (2006) Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol 148:688-695
53. Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cellular Mol and Life Sci 64:2090-2103
54. Salvamini D, Wang ZQ, Wyatt PS, Bourdon BM, Marino MH, Manning PT, Currie MG (1996) Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118:829-838
55. Salvemini D, Zhi-Ojang W, Bourdon DM, Stern MK, Currie MG, Manning PT (1996) Evidence of peroxynitrite involvement in the carrageenan-induced paw edema. Eur J Pharmacol 303:217-220
56. Sawynok J, Reid A (2002) Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine. Eur J Pharmacol 450:153-162
57. Shang Y, Jiang YX, Ding ZJ, Shen AL, Xu SP, Yuan SY, Yao SL (2010) Valproic acid attenuates the multiple-organ dysfunction in a rat model of septic shock. Chinese Med J 123:2682-2687
58. L-Shin S, Yatham Lakshmi N, Yen Chin-Bin Ravindran Arun V (2005) Effect of valproate on plasma levels of interleukin-6 in health male human. Int Clin Psychopharmacol 20:295-298
59. Tverskoy M, Oz Y, Isakson A, Finger J, Bradley EL Jr, Kissin I (1994) Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia. Anesth Analg 78:205-209
60. Vaden DI, Ding D, Peterson B, Geenberg MI (2001) Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 276:15466-15471
61. Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH (2006) Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 112:116-138
62. Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer drugs. Int J Cancer 112:171-178
63. Vion-Dury J, Cupo A, Jarry T (1987) Analgesic properties of valproic acid might be related to the encephalin system in rat brain. Brain Res 408:243-246
64. Watt AP, Schock BC, Ennis M (2005) Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Current Drug Targets-Inflammation Allergy 4:415-423
65. Willmore LJ (2003) Divalproex and epilepsy. Psychopharmacol Bull 37:43-53
66. Ximenes JCM, Lima-Verde EC, Naffah-Mazzacoratti MG, Viana GSB (2012) Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action. Neurosci and Med 3:107-123
67. Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187:447-463
68. Zakusov VV, Ostrovskaya RU, Bulayev VM (1983) GABA-opiates interactions in the activity of analgesics. Archives of Int Pharmacodynamics and Ther 265:61-75